| scholarly article | Q13442814 |
| P356 | DOI | 10.1126/SCITRANSLMED.AAC4925 |
| P698 | PubMed publication ID | 26606967 |
| P50 | author | Sai T Reddy | Q55473731 |
| Daniela S Thommen | Q58701244 | ||
| Kea Martin | Q86519329 | ||
| Tarik A Khan | Q87199068 | ||
| P2093 | author name string | Nadia Harbeck | |
| Alfred Zippelius | |||
| Hans Kreipe | |||
| Michael von Bergwelt-Baildon | |||
| Matthias Christgen | |||
| Philipp Müller | |||
| Spasenija Savic | |||
| Oleg Gluz | |||
| Ulrike Nitz | |||
| Katharina Glatz | |||
| Matthias Kreuzaler | |||
| P2860 | cites work | Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate | Q34880994 |
| P433 | issue | 315 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | trastuzumab | Q412616 |
| P304 | page(s) | 315ra188 | |
| P577 | publication date | 2015-11-01 | |
| P1433 | published in | Science Translational Medicine | Q1573955 |
| P1476 | title | Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade | |
| P478 | volume | 7 |
| Q39026137 | A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions |
| Q61446009 | A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer |
| Q91253090 | A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma |
| Q47861842 | A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer |
| Q64069325 | Acquired Resistance to Antibody-Drug Conjugates |
| Q38824661 | Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling |
| Q38937896 | Adaptive immunity programmes in breast cancer. |
| Q39210427 | Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review |
| Q47568807 | Antibody-Drug Conjugates as Cancer Therapeutics: Past, Present, and Future |
| Q53739135 | Antibody-Drug Conjugates for Cancer Therapy. |
| Q47851750 | Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments |
| Q38864720 | Antibody-drug conjugates for cancer therapy. |
| Q47774335 | Antibody-drug conjugates: targeted delivery and future prospects |
| Q47722599 | Antitumor Antibodies Can Drive Therapeutic T Cell Responses |
| Q38628198 | Breast Cancer Immunotherapy: Facts and Hopes |
| Q39330060 | Breast Cancer and Transplantation. |
| Q89918629 | Breast cancer immunology and immunotherapy: targeting the programmed cell death protein-1/programmed cell death protein ligand-1 |
| Q88716138 | Breast cancer: T-DM1 - an important agent in the history of breast cancer management |
| Q37687139 | CD64-directed microtubule associated protein tau kills leukemic blasts ex vivo. |
| Q57120564 | Cancer stem cells and HER2 positive breast cancer: The story so far |
| Q57110111 | Checkpoint blockade in the treatment of breast cancer: current status and future directions |
| Q90484961 | Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond |
| Q41162193 | Closing the gap: astrocytes and brain metastasis |
| Q90269095 | Crosstalk between HER2 and PD-1/PD-L1 in Breast Cancer: From Clinical Applications to Mathematical Models |
| Q92002867 | Dawn of Monitoring Regulatory T Cells in (Pre-)clinical Studies: Their Relevance Is Slowly Recognised |
| Q92293280 | Development of a human immuno-oncology therapeutic agent targeting HER2: targeted delivery of granzyme B |
| Q39094764 | Elements of cancer immunity and the cancer-immune set point |
| Q91989251 | Emerging strategies in neoadjuvant treatment of patients with HER2-positive early breast cancer |
| Q104105690 | Enhancing anti-tumour efficacy with immunotherapy combinations |
| Q60047596 | Exceptional and Durable Responses to TDM-1 After Trastuzumab Failure for Breast Cancer Skin Metastases: Potential Implications of an Immunological Sanctuary |
| Q90281584 | GEF-H1 Signaling upon Microtubule Destabilization Is Required for Dendritic Cell Activation and Specific Anti-tumor Responses |
| Q49571851 | HER2 overexpression triggers an IL-1α pro-inflammatory circuit to drive tumorigenesis and promote chemotherapy resistance |
| Q49933578 | Immune Checkpoint Blockade for Breast Cancer |
| Q92176250 | Immunotherapy and targeted therapy combinations in metastatic breast cancer |
| Q91942638 | Immunotherapy in Esophagogastric Adenocarcinoma |
| Q47271330 | Improved Tumor Penetration and Single-Cell Targeting of Antibody Drug Conjugates Increases Anticancer Efficacy and Host Survival. |
| Q64103583 | Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer |
| Q47156322 | Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy. |
| Q57107866 | Is there a role for immunotherapy in HER2-positive breast cancer? |
| Q89840115 | Landscape of combination therapy trials in breast cancer brain metastasis |
| Q64268826 | Maytansine-bearing antibody-drug conjugates induce in vitro hallmarks of immunogenic cell death selectively in antigen-positive target cells |
| Q91992316 | Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer |
| Q38765188 | Multiscale Modeling of Antibody-Drug Conjugates: Connecting Tissue and Cellular Distribution to Whole Animal Pharmacokinetics and Potential Implications for Efficacy. |
| Q39375196 | Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies. |
| Q26766540 | New developments for antibody-drug conjugate-based therapeutic approaches |
| Q57111360 | New horizons in breast cancer: the promise of immunotherapy |
| Q47661007 | Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer. |
| Q41718196 | Programmed death-ligand 1 (PD-L1) expression in tumour cell and tumour infiltrating lymphocytes of HER2-positive breast cancer and its prognostic value |
| Q38798525 | Prospects and progress of antibody-drug conjugates in solid tumor therapies |
| Q64991628 | Quantitative pharmacology in antibody-drug conjugate development: armed antibodies or targeted small molecules? |
| Q45728543 | Recent Developments in ADC Technology: Preclinical Studies Signal Future Clinical Trends |
| Q92316377 | Regulation of Immunity in Breast Cancer |
| Q92981384 | Resident memory CD8+ T cells within cancer islands mediate survival in breast cancer patients |
| Q95840405 | Revisiting the role of CD4+ T cells in cancer immunotherapy-new insights into old paradigms |
| Q41996352 | Roles for Innate Immunity in Combination Immunotherapies |
| Q93047745 | Sequential Anti-PD1 Therapy Following Dendritic Cell Vaccination Improves Survival in a HER2 Mammary Carcinoma Model and Identifies a Critical Role for CD4 T Cells in Mediating the Response |
| Q61796812 | Significance of baseline neutrophil-to-lymphocyte ratio for progression-free survival of patients with HER2-positive breast cancer treated with trastuzumab emtansine |
| Q39182945 | Strategies and challenges for the next generation of antibody-drug conjugates |
| Q92615075 | Targeting natural killer cells in solid tumors |
| Q36678851 | The Basis of Oncoimmunology |
| Q39456999 | The immune contexture in cancer prognosis and treatment |
| Q89727324 | Trastuzumab Emtansine: Mechanisms of Action and Resistance, Clinical Progress, and Beyond |
| Q90644277 | Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer |
Search more.